GAMMA Investing’s Ultragenyx Pharmaceutical RARE Stock Holding History

GAMMA Investing’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.13K	Sell	341 -1,578	-82%	-$37.9K	﹤0.01%	3636
2026 Q2	$64.1K	Buy	1,919 +1,150	+150%	+$28.6K	﹤0.01%	2130
2026 Q1	$16.1K	Buy	769 +184	+31%	+$4.14K	﹤0.01%	2834
2025 Q4	$13.5K	Buy	585 +389	+198%	+$12.8K	﹤0.01%	2831
2025 Q3	$5.9K	Sell	196 -411	-68%	-$12.3K	﹤0.01%	3105
2025 Q2	$22.1K	Sell	607 -140	-19%	-$5.05K	﹤0.01%	2400
2025 Q1	$27K	Buy	747 +323	+76%	+$13.4K	﹤0.01%	2210
2024 Q4	$17.8K	Buy	424 +29	+7%	+$1.44K	﹤0.01%	2323
2024 Q3	$21.9K	Buy	395 +267	+209%	+$13.6K	﹤0.01%	2051
2024 Q2	$5.26K	Sell	128 -876	-87%	-$37.4K	﹤0.01%	2556
2024 Q1	$46.9K	Buy	1,004 +865	+622%	+$40.8K	0.01%	1087
2023 Q4	$6.13K	Buy	+139	New	+$5.39K	﹤0.01%	2143

Other funds holding RARE

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's RARE Position: Q3 2026 in Review

GAMMA Investing reduced its Ultragenyx Pharmaceutical (RARE) stake by 82% in Q3 2026, selling an estimated $37.9K and leaving 341 shares worth $5.13K. The position accounts for ﹤0.01% of the portfolio, ranked #3636.

GAMMA Investing first reported a position in RARE in Q4 2023 and has held it in 12 quarters since. The position peaked at $64.1K in Q2 2026. 4 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

GAMMA Investing held 341 shares of Ultragenyx Pharmaceutical worth $5.13K as of Q3 2026.
GAMMA Investing sold 1,578 Ultragenyx Pharmaceutical shares in Q3 2026, an estimated $37.9K.
Ultragenyx Pharmaceutical made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3636 holding.
GAMMA Investing first reported a position in Ultragenyx Pharmaceutical in Q4 2023 and has held it in 12 quarters since.
GAMMA Investing's Ultragenyx Pharmaceutical position peaked at $64.1K in Q2 2026.
4 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.